Clinical Trial Update: Mavacamten in Obstructive Hypertrophic Cardiomyopathy

View source ↗

Summary

A completed clinical trial evaluating mavacamten for obstructive hypertrophic cardiomyopathy is summarized in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM) | Status: COMPLETED